Conditional Survival of Nasopharyngeal Carcinoma in the Era of Intensive Modulated Radiation Therapy
J. Wang,X. Huang,S. Sun,K. Wang,Y. Qu,X. Chen,R. Wu,Y. Zhang,Q. Liu,J. Zhang,J. Luo,J. Xiao,L. Gao,G. Xu,J. Yi
DOI: https://doi.org/10.1016/j.ijrobp.2020.07.350
2020-01-01
Abstract:In IMRT era, nasopharyngeal carcinoma (NPC) achieves the 5-year overall survival (OS) rate of 70-90%, which can be considered a static prediction of prognosis at diagnosis. However, the OS probability evolves over time and this static prognosis evaluation on the basis of initial diagnosis or therapy is not very informative for a patient who has survived for a long-term. This study aimed to make a conditional survival (CS) analysis in the population of Chinese NPC treated with modern radiation technique. NPC patients who were treated with definitive IMRT with or without chemotherapy in our institution between 2003 and 2017 were identified for analysis. CS estimates and annual hazard of death according to TNM stage were assessed. Statistical analyses were performed using R (version 3.6.2) and SPSS (version 22.0). A total of 1995 patients were eligible for analysis. The median age of the whole cohort was 47 and 73% of the study patients were male. According to the AJCC 8th edition of TNM stage classification, stage I, II, III and IVA accounted for 2.1%, 12.8%, 43.3% and 41.8%, respectively. Between 2003 and 2010, IMRT was the predominant technique. Afterwards, the utility of VMAT increased remarkably and became the mainstay technique since 2012. The median follow-up time was 59.6 months and the Kaplan-Meier estimate of the median censoring distribution was 73.5 months. For the overall cohort, the 5-y OS rate estimated from baseline was 79% and increased to 79.5%, 80.4%, 83.2%, 85.4% and 85.8% at conditional survival time points 1 to 5 years after diagnosis. With regard to stage III disease, the 5-y survival probabilities increased from 86.7% to 87.2%, 88.3%, 89.7%, 91.1% and 90.7% at 1 to 5 years of event free follow up. Likewise, subgroup of stage IV presented the 5-y OS of 66.2% at baseline and subsequently 66.5%, 67.9%, 71.4%, 75.3% and 76.3% at 1 to 5 years of event free follow up. For the overall cohort, the annual hazard for death was 4.3% at the first year and decreased to 3.9% at the 5 year. Accordingly, the annual hazards for death were changed from 2.7% to 2.3%, and 7.6% to 7.0% for stage III and IV diseases, respectively. Long-term outcome of NPC patients treated with IMRT dynamically improved over time in the epidemic region, which could provide important information in assisting the decision making for tailored therapy and follow up regimen.